OncoMatch/Clinical Trials/NCT06520319

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

Is NCT06520319 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 68Ga-MGS5 for medullary thyroid carcinoma.

Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06520319Data as of May 2026

Treatment: 68Ga-MGS5 — Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Thyroid Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify